Mem Inst Oswaldo Cruz, Rio de Janeiro, VOLUME 119 | 2024
Perspective

The Oxente Chagas Bahia Project: evaluating the efficacy of a rapid diagnostic test and treatments for Chagas disease

Fred Luciano Neves Santos1,2,3,+, Tycha Bianca Sabaini Pavan1,2, Cristiane Siqueira Valle4, Daniel Dias Sampaio2, Larissa Carvalho Medrado Vasconcelos1,2, Maria Hermoso Cristóbal4, Ângelo Antônio Oliveira Silva1,2, Cátia Martins de Oliveira5, Raquel Santos de Souza5, Carmen Nila Phang Romero Casas5, André Daher3,4, Isadora Cristina de Siqueira2,3,6

1Fundação Oswaldo Cruz-Fiocruz, Instituto Gonçalo Moniz, Laboratório Avançado de Saúde Pública, Salvador, BA, Brasil
2Fundação Oswaldo Cruz-Fiocruz, Instituto Gonçalo Moniz, Grupo de Pesquisa Interdisciplinar em Biotecnologia e Epidemiologia de Doenças Infecciosas, Salvador, BA, Brasil
3Fundação Oswaldo Cruz-Fiocruz, Vice-Presidência de Pesquisa e Coleções Biológicas, Programa de Pesquisa Translacional em Doenças de Chagas, Rio de Janeiro, RJ, Brasil
4Fundação Oswaldo Cruz-Fiocruz, Vice-Presidência de Pesquisa e Coleções Biológicas, Plataforma de Pesquisa Clínica, Rio de Janeiro, RJ, Brasil
5Fundação Oswaldo Cruz-Fiocruz, Centro de Desenvolvimento Tecnológico em Saúde, Rio de Janeiro, RJ, Brasil
6Fundação Oswaldo Cruz-Fiocruz, Instituto Gonçalo Moniz, Laboratório de Investigação em Saúde Global e Doenças Negligenciadas, Salvador, BA, Brasil

DOI: 10.1590/0074-02760240140
618 views 202 downloads
Print Email PDF
ABSTRACT

Chagas disease (CD), caused by Trypanosoma cruzi, is a life-threatening neglected anthropozoonosis primarily transmitted by triatomine bugs. Affecting an estimated 5.7 million people globally, CD has significant morbidity and mortality, particularly in Latin America. The Oxente Chagas Bahia Project aims to screen approximately 30,000 individuals, validate a rapid diagnostic test in a real-world setting, and provide crucial data on its diagnostic performance and cost-effectiveness. Additionally, a biobank will be established to support further research on disease biomarkers and treatment cure rates. By enhancing access to timely diagnosis and treatment, the project will evaluate a strategy to reduce the CD burden.

key words: rapid diagnostic test diagnostic performance cost-effectiveness Chagas disease antiparasitic treatment
REFERENCES
01. WHO - World Health Organization. Chagas disease (also known as American trypanosomiasis). [updated 2024 April 4; cited 2024 Jun 27]. Available from: https://www.who.int/news-room/factsheets/ detail/chagas-disease-(american-trypanosomiasis).
02. MS - Ministério da Saúde. Portaria nº 57, de 30 de outubro de 2018. Protocolo clínico e diretrizes terapêuticas doença de Chagas. Brasília: Ministério da Saúde/Secretaria de Ciência, Tecnologia e Insumos Estratégicos; 2018.
03. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R, et al. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother. 2009; 64(6): 1139-47.
04. Dias JCP, Ramos Jr AN, Gontijo ED, Luquetti A, Shikanai-Yasuda MA, Coura JR, et al. II Brazilian Consensus on Chagas Disease, 2015. Rev Soc Bras Med Trop. 2016; 49(Suppl. 1): 3-60.
05. Martins-Melo FR, Carneiro M, Ramos AN, Heukelbach J, Ribeiro ALP, Werneck GL. The burden of neglected tropical diseases in Brazil, 1990-2016: a subnational analysis from the Global Burden of Disease Study 2016. PLoS Negl Trop Dis. 2018; 12(6): e0006559.
06. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013; 13(4): 342-8.
07. Chaves GC, Arrieche MA-S, Rode J, Mechali D, Reis PO, Alves RV, et al. Estimación de la demanda de medicamentos antichagásicos: una contribución para el acceso en América Latina. Rev Panam Salud Publica. 2017; 41: e45.
08. PAHO - Pan American Health Organization. Guidelines for the diagnosis and treatment of Chagas disease. Washington DC: Pan American Health Organization; 2019.
09. Silva ED, Silva AAO, Santos EF, Leony LM, Freitas NEM, Daltro RT, et al. Development of a new lateral flow assay based on IBMP- 8.1 and IBMP-8.4 chimeric antigens to diagnose Chagas disease. Biomed Res Int. 2020; 2020: 1803515.
10. Marchiol A, Sanchez ACF, Caicedo A, Segura M, Bautista J, Sotelo MSA, et al. Laboratory evaluation of eleven rapid diagnostic tests for serological diagnosis of Chagas disease in Colombia. PLoS Negl Trop Dis. 2023; 17(8): e0011547.
11. López R, García A, Aruni JJC, Balboa V, Rodríguez A, Erkosar B, et al. Comparative evaluation of lateral flow assays to diagnose chronic Trypanosoma cruzi infection in Bolivia. PLoS Negl Trop Dis. 2024; 18(3): e0012016.
12. Iturra JAD, Leony LM, Medeiros FAC, Souza Filho JA, Siriano LR, Tavares SB, et al. A multicenter comparative study of the performance of four rapid immunochromatographic tests for the detection of anti-Trypanosoma cruzi antibodies in Brazil. Front Med (Lausanne). 2023; 10: 1031455.
13. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019; 95: 103208.
14. Martins-Melo FR, Ramos AN, Alencar CH, Heukelbach J. Prevalence of Chagas disease in Brazil: a systematic review and metaanalysis. Acta Trop. 2014; 130: 167-74.
15. Pavan TBS, Dias DP, Cangussú MM, Dutra VPP, Sampaio DD, Santos FLN. Seroepidemiology of Chagas disease in at-risk individuals in Caraíbas, a city with high endemicity in Bahia State, Brazil. Front Public Health. 2023; 11: 1196403.

Financial support: INOVA Fiocruz Pesquisa Clínica em Doença de Chagas (VPPCB-001-FIO-22-2-11), FAPESB/SECTI (Universal, proposal NºAPP0007/2023).
ICS and FLNS are CNPq research grantees (process numbers 316456/2021-7 and 309263/2020-4, respectively).
+ Corresponding author: fred.santos@fiocruz.br
ORCID https://orcid.org/0000-0002-3944-0818
Received 04 July 2024
Accepted 12 September 2024

HOW TO CITE
Santos FLN, Pavan TBS, Valle CS, Sampaio DD, Vasconcelos LCM, Cristóbal MH, et al. The Oxente Chagas Bahia Project: evaluating the efficacy of a rapid diagnostic test and treatments for Chagas disease. Mem Inst Oswaldo Cruz. 2024; 119: e240140.

Our Location

Memórias do Instituto Oswaldo Cruz

Av. Brasil 4365, Castelo Mourisco 
sala 201, Manguinhos, 21040-900 
Rio de Janeiro, RJ, Brazil

Tel.: +55-21-2562-1222

This email address is being protected from spambots. You need JavaScript enabled to view it.

Support Program

logo iocb

logo governo federal03h 
faperj   cnpq capes

Site Map

Member Login